DUBLIN--(BUSINESS WIRE)--The "Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2023" report has been added to ResearchAndMarkets.com's offering.
"Rheumatoid Arthritis Therapeutics in AsiaPacific Markets to 2023 Novel JAK and IL6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster AntiTNFs" provides the current AsiaPacific RA market contains novel products, including sirukumab, an antiIL6 human mAb; Peficitinib, Upadacitinib and Filgotinib, which are JAK1 inhibitors; Olokizumab, an antiIL6 humanized IgG4 mAb; and RCT18, a recombinant human Blymphocyte stimulating factor (BLyS) receptorantibody fusion protein.
The RA therapeutic market has become very competitive due to the high number of new drug approvals. Competition is fierce, particularly among TNFa inhibitors, which dominate the treatment market for RA patients who are refractory to traditional diseasemodifying antirheumatic drugs (DMARD).
Despite this, 30% of RA patients fail to attain a clinical response when treated with TNFa inhibitors. However, other targeted programs, as well as newly marketed smallmolecule DMARDs such as the Janus kinase (JAK) inhibitor Xeljanz (tofacitinib), have the potential to replace ineffective TNFa inhibitors. Recently published study results of Xeljanz have shown a significant reduction in the risk of developing cardiac diseases such as heart attack and stroke in patients with RA.
The advent of biologic diseasemodifying antirheumatic drugs (DMARD) has boosted the rheumatoid arthritis (RA) market tremendously over the last two decades. Growth is expected to continue at a moderate pace from around $5.6 billion in 2016 to more than $9.5 billion in 2023 at a compound annual growth rate (CAGR) of over 8% in the AsiaPacific (APAC) markets of India, Australia, China, South Korea and Japan. Japan accounted for the majority of the market in 2016 with a 65.4% share, followed by China, Australia, India and South Korea with about 12.7%, 8.6%, 8.1% and 5.2% respectively.
Recently approved therapies anticipated to have a high impact include Eli Lilly and Incyte's baricitinib and Sanofi and Regeneron's sarilumab. Along with recently approved therapies, the entry of new therapies over the forecast period will stimulate market growth. Promising pipeline candidates include Johnson & Johnson (J&J) and GlaxoSmithKline (GSK)'s sirukumab, and Galapagos's filgotinib. Galapagos entered into a global collaboration agreement with Gilead in 2015 to develop and commercialize filgotinib for the treatment of inflammatory indications.
Key Topics Covered:
2 Marketed Products
3 Product Pipeline
4 Clinical Trial Analysis
5 Multi-Scenario Forecast
6 Market Dynamics (Drivers and Barriers) of RA Therapeutics Market
7 Deals and Strategic Consolidations
- Daiichi Sankyo
- Bristol-Myers Squibb
- Eli Lilly
- Johnson & Johnson
For more information about this report visit https://www.researchandmarkets.com/research/zdjfbm/rheumatoid?w=4